샘플 요청 목록

 카트 문의
시장보고서
상품코드
2044625

전이성 암 치료제 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Metastatic Cancer Drug Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 186 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,690,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 13,079,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 16,320,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 전이성 암 치료제 시장은 암 치료가 보다 개인화되고 증거에 기반한 환자 중심의 치료 모델로 전환됨에 따라 꾸준히 성장하고 있습니다. 전이성 암은 악성 세포가 원발성 종양에서 원격 장기로 퍼져나가면서 발생하며, 복잡한 임상적 문제를 야기하고 장기간의 전신 요법을 필요로 합니다. 2026년 시장 규모는 905억 달러로 평가되었고, 2033년까지 1,464억 달러에 달할 것으로 예측됩니다. 또한, 예측 기간 동안 CAGR 7.10%를 기록할 전망입니다. 이러한 성장은 암 발병률 증가, 진단 능력 향상, 치료 접근성 확대, 진행성 암 치료의 지속적인 제약 혁신에 의해 뒷받침되고 있습니다.

시장 인사이트

시장에서는 광범위한 세포 독성 치료에서 특정 종양 생물학, 면역 반응 메커니즘 및 분자 이상을 표적으로 하는 치료법으로의 명확한 전환을 볼 수 있습니다. 화학요법은 특히 병용요법에서 중요한 역할을 계속하고 있지만, 표적치료, 면역요법, 호르몬요법, 단일클론항체, 혈관신생억제제, 암백신의 임상적 중요성이 점점 더 커지고 있습니다. 의사들은 치료법 선택을 유도하고 치료 결과를 개선하기 위해 바이오마커 검사, 유전체 시퀀싱 및 동반 진단을 점점 더 많이 활용하고 있습니다. 경구용 약물이 특정 환자들에게 편리함을 제공하고 있지만, 주사제 치료는 여전히 병원이나 전문 의료기관에서 필수적인 치료법입니다. 또한, 전문 약국 서비스를 이용할 수 있는 기회가 늘어나면서 환자들이 복잡한 치료 일정, 부작용, 복약 순응도 요건을 관리하는 데 도움이 되고 있습니다.

성장 촉진요인

전이성 암 치료제 시장의 주요 촉진요인은 진행성, 재발성 또는 치료 저항성 암 치료를 필요로 하는 환자 수 증가입니다. 유방암, 폐암, 대장암, 전립선암, 악성 흑색종, 난소암, 췌장암, 신장암, 간암은 여전히 치료 수요의 주요 영역입니다. 면역종양학의 발전으로 일부 종양 유형에 대한 치료 기준이 변화하고 있으며, 표적치료제는 치료 가능한 돌연변이가 있는 암에 대한 보다 정밀한 개입을 가능하게 하고 있습니다. 인식 증가, 스크리닝의 개선, 영상 진단 기술의 향상으로 전이 진행을 조기에 발견할 수 있게 되었습니다. 또한, 병원과 암 치료 센터에서는 약물 치료와 진단, 모니터링, 완화의료, 생존계획 등을 결합한 다직종 연계 치료 모델을 도입하고 있습니다.

비즈니스 기회

이 시장은 유효성, 안전성, 지속성을 개선한 차세대 치료제를 개발하는 제약사들에게 큰 기회를 제공합니다. 의약품 개발 기업들은 면역관문억제제, 키나아제 억제제, 항체치료제, 병용요법 및 신규 암 백신 플랫폼에 집중하고 있습니다. 췌장암, 간암, 난소암, 그리고 특정 공격성이 높은 폐암과 신장암 등 치료 옵션이 제한되어 있는 암 분야에는 큰 기회가 존재합니다. 바이오마커 기반 임상시험, 실제 데이터 및 환자 지원 프로그램에 투자하는 기업은 병원, 전문 클리닉 및 암 치료 센터에서의 도입을 강화할 수 있습니다. 신흥국에서도 공공 및 민간 의료 투자를 통해 암 의료 인프라가 개선되고 첨단 의약품에 대한 접근성이 확대됨에 따라 매력적인 성장 잠재력을 보여주고 있습니다.

지역별 분석

북미는 선진화된 의료 인프라, 높은 혁신적 치료법 보급률, 우수한 급여제도, 활발한 종양학 연구 활동으로 인해 전이성 암 치료제 시장에서 선도적인 위치를 유지할 것으로 예측됩니다. 주요 기업과 전문 암센터의 존재가 새로운 치료법의 신속한 도입을 뒷받침하고 있습니다. 유럽에서는 체계화된 암 치료 프로그램, 규제적 지원, 정밀의료(Precision Medicine)의 활용 확대에 힘입어 성장세를 이어가고 있습니다. 아시아태평양은 암 유병률 증가, 의료비 증가, 병원 네트워크 확대, 임상시험 참여 확대 등에 힘입어 높은 잠재력을 지닌 지역으로 부상하고 있습니다. 라틴아메리카와 중동 및 아프리카에서는 유통 채널의 개선, 전문 의료의 확대, 정부의 의료 이니셔티브를 통해 전이성 암 치료에 대한 접근성이 점차 개선되고 있습니다.

주요 기업

경쟁 환경은 종양학 파이프라인, 임상 개발, 규제 당국의 승인, 전략적 제휴에 투자하는 세계 제약사별로 형성되고 있습니다. 전이성 암 치료제 시장의 주요 기업으로는 다음과 같은 기업들이 있습니다.

  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Eisai Co., Ltd.
  • Incyte Corporation
  • Ipsen S.A.

이들 기업은 표적치료제, 면역치료제, 병용요법, 라이프사이클 관리 전략을 통해 포트폴리오를 강화하기 위해 노력하고 있습니다. 이러한 투자는 주요 암종에 대한 지속적인 혁신을 촉진하고 전이성 질환 환자들에게 더 많은 치료 옵션을 제공할 수 있을 것으로 기대됩니다.

암 치료의 개별화가 진행됨에 따라 병원, 연구기관, 전문 클리닉, 약국, 제약사 간의 협력 강화가 시장에 긍정적인 영향을 미칠 것으로 예측됩니다. 병원 약국, 소매 약국, 온라인 약국, 전문 약국 등 유통 채널은 의약품의 적시 공급과 지속적인 관리를 보장하는 데 점점 더 중요해지고 있습니다. 생존기간 연장, 삶의 질(QOL), 관리 가능한 독성에 대한 관심이 높아지면서 처방 패턴에 계속 영향을 미칠 것입니다. 전이성 암 치료제 시장은 지속적인 임상 연구 개발 및 첨단 치료제에 대한 접근성 확대에 따라 선진국과 신흥국에서 지속적인 성장이 예상됩니다. 이와 함께 보험사들은 암 치료제의 치료 효과, 비용 효율성, 환자의 접근성을 고려하여 암 치료제를 평가하는 경향이 강해지고 있습니다. 이에 따라 제약사들은 명확한 임상적 가치를 입증하고, 임상의를 교육하고, 치료 중단을 줄일 수 있는 지원 프로그램을 구축할 것을 촉구하고 있습니다. 이러한 노력은 시장 침투율을 높이는 동시에 환자들이 장기간 적절한 치료를 지속할 수 있도록 지원할 것으로 기대됩니다.

세분화

약품 등급별

  • 화학요법
  • 표적치료
  • 면역요법
  • 호르몬 요법
  • 단일클론항체
  • 혈관 신생 억제제
  • 암 백신
  • 기타

암 유형별

  • 유방암
  • 폐암
  • 대장암
  • 전립선암
  • 악성 흑색종
  • 난소암
  • 췌장암
  • 신장암
  • 간암
  • 기타

투여 경로별

  • 경구
  • 주사제
  • 기타

유통채널별

  • 병원 약국
  • 소매 약국
  • 온라인 약국
  • 전문약국

최종 사용자별

  • 병원
  • 암 치료센터
  • 전문 클리닉
  • 연구기관
  • 기타

지역별

  • 북미
  • 북미
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 전이성 암 치료제 시장 전망, 2020년-2033년

제4장 북미의 전이성 암 치료제 시장 전망, 2020년-2033년

제5장 유럽의 전이성 암 치료제 시장 전망, 2020년-2033년

제6장 아시아태평양의 전이성 암 치료제 시장 전망, 2020년-2033년

제7장 라틴아메리카의 전이성 암 치료제 시장 전망, 2020년-2033년

제8장 중동 및 아프리카의 전이성 암 치료제 시장 전망, 2020년-2033년

제9장 경쟁 구도

제10장 부록

LSH 26.06.08

The global Metastatic Cancer Drug Market is expanding steadily as oncology care moves toward more personalized, evidence-based, and patient-centered treatment models. Metastatic cancer occurs when malignant cells spread from the original tumor site to distant organs, creating complex clinical challenges and requiring long-term systemic therapy. The market is valued at US$ 90.5 Bn in 2026 and is projected to reach US$ 146.4 Bn by 2033, growing at a CAGR of 7.10% during the forecast period. Growth is supported by rising cancer incidence, stronger diagnostic capabilities, broader treatment access, and continued pharmaceutical innovation across advanced cancer care.

Market Insights

The market is witnessing a clear shift from broad cytotoxic approaches toward therapies that target specific tumor biology, immune response mechanisms, and molecular abnormalities. Chemotherapy continues to play an important role, particularly in combination regimens, but targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, angiogenesis inhibitors, and cancer vaccines are gaining wider clinical relevance. Physicians are increasingly using biomarker testing, genomic sequencing, and companion diagnostics to guide therapy selection and improve treatment outcomes. Oral drugs are improving convenience for selected patients, while injectable therapies remain essential in hospital and specialty settings. The growing availability of specialty pharmacy services is also helping patients manage complex treatment schedules, adverse effects, and adherence requirements.

Drivers

A key driver of the Metastatic Cancer Drug Market is the increasing number of patients requiring treatment for advanced, recurrent, or treatment-resistant cancers. Breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, pancreatic cancer, kidney cancer, and liver cancer remain major areas of therapeutic demand. Advances in immuno-oncology have changed treatment standards for several tumor types, while targeted medicines are enabling more precise intervention in cancers with actionable mutations. Rising awareness, improved screening, and better imaging technologies are supporting earlier identification of metastatic progression. In addition, hospitals and cancer treatment centers are adopting multidisciplinary care models that combine drug therapy with diagnostics, monitoring, palliative support, and survivorship planning.

Business Opportunity

The market offers strong opportunities for pharmaceutical companies developing next-generation therapies with improved efficacy, safety, and durability of response. Drug developers are focusing on immune checkpoint inhibitors, kinase inhibitors, antibody-based therapies, combination treatments, and novel cancer vaccine platforms. Significant opportunity exists in cancers with limited treatment options, including pancreatic cancer, liver cancer, ovarian cancer, and certain aggressive lung and kidney cancers. Companies that invest in biomarker-led clinical trials, real-world evidence, and patient support programs can strengthen adoption across hospitals, specialty clinics, and cancer treatment centers. Emerging economies also present attractive growth potential as oncology infrastructure improves and access to advanced medicines expands through public and private healthcare investments.

Region Analysis

North America is expected to maintain a prominent position in the Metastatic Cancer Drug Market due to advanced healthcare infrastructure, high adoption of innovative therapies, strong reimbursement systems, and extensive oncology research activity. The presence of leading pharmaceutical companies and specialized cancer centers supports rapid integration of new treatment options. Europe continues to grow through structured cancer care programs, regulatory support, and increasing use of precision medicine. Asia Pacific is emerging as a high-potential region, driven by rising cancer prevalence, growing healthcare expenditure, expanding hospital networks, and greater participation in clinical trials. Latin America and the Middle East & Africa are gradually improving access to metastatic cancer treatment through better distribution channels, specialty care expansion, and government health initiatives.

Key Players

The competitive environment is shaped by global pharmaceutical leaders investing in oncology pipelines, clinical development, regulatory approvals, and strategic collaborations. Key players in the Metastatic Cancer Drug Market include:

  • Pfizer Inc.
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Eisai Co., Ltd.
  • Incyte Corporation
  • Ipsen S.A.

These companies are working to strengthen their portfolios through targeted therapies, immunotherapies, combination regimens, and lifecycle management strategies. Their investments are expected to support continued innovation across major cancer types and improve treatment choices for patients with metastatic disease.

As oncology treatment becomes more individualized, the market is expected to benefit from stronger collaboration among hospitals, research institutes, specialty clinics, pharmacies, and pharmaceutical manufacturers. Distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies are becoming increasingly important in ensuring timely drug availability and continuity of care. The growing focus on survival improvement, quality of life, and manageable toxicity will continue to influence prescribing patterns. With ongoing clinical research and expanding access to advanced therapies, the Metastatic Cancer Drug Market is positioned for sustained growth across developed and emerging regions. In parallel, payers are increasingly assessing oncology drugs through outcomes, affordability, and patient access considerations. This is encouraging manufacturers to demonstrate clear clinical value, support education for clinicians, and build assistance programs that reduce treatment disruption. Such initiatives are likely to improve market penetration while helping patients remain on appropriate therapies for longer periods.

Segmentation

By Drug Class

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormonal Therapy
  • Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • Cancer Vaccines
  • Others

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Kidney Cancer
  • Liver Cancer
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Pharmacies

By End User

  • Hospitals
  • Cancer Treatment Centers
  • Specialty Clinics
  • Research Institutes
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Metastatic Cancer Drug Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 3.1. Global Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 3.1.1. Oral
    • 3.1.2. Injectable
    • 3.1.3. Others
  • 3.2. Global Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.2.1. Hospital Pharmacies
    • 3.2.2. Retail Pharmacies
    • 3.2.3. Online Pharmacies
    • 3.2.4. Specialty Pharmacies
  • 3.3. Global Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 3.3.1. Chemotherapy
    • 3.3.2. Targeted Therapy
    • 3.3.3. Immunotherapy
    • 3.3.4. Hormonal Therapy
    • 3.3.5. Monoclonal Antibodies
    • 3.3.6. Angiogenesis Inhibitors
    • 3.3.7. Cancer Vaccines
    • 3.3.8. Others
  • 3.4. Global Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 3.4.1. Breast Cancer
    • 3.4.2. Lung Cancer
    • 3.4.3. Colorectal Cancer
    • 3.4.4. Prostate Cancer
    • 3.4.5. Melanoma
    • 3.4.6. Ovarian Cancer
    • 3.4.7. Pancreatic Cancer
    • 3.4.8. Kidney Cancer
    • 3.4.9. Liver Cancer
    • 3.4.10. Others
  • 3.5. Global Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospitals
    • 3.5.2. Cancer Treatment Centers
    • 3.5.3. Specialty Clinics
    • 3.5.4. Research Institutes
    • 3.5.5. Others
  • 3.6. Global Metastatic Cancer Drug Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 4.1. North America Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 4.1.1. Oral
    • 4.1.2. Injectable
    • 4.1.3. Others
  • 4.2. North America Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.2.1. Hospital Pharmacies
    • 4.2.2. Retail Pharmacies
    • 4.2.3. Online Pharmacies
    • 4.2.4. Specialty Pharmacies
  • 4.3. North America Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 4.3.1. Chemotherapy
    • 4.3.2. Targeted Therapy
    • 4.3.3. Immunotherapy
    • 4.3.4. Hormonal Therapy
    • 4.3.5. Monoclonal Antibodies
    • 4.3.6. Angiogenesis Inhibitors
    • 4.3.7. Cancer Vaccines
    • 4.3.8. Others
  • 4.4. North America Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 4.4.1. Breast Cancer
    • 4.4.2. Lung Cancer
    • 4.4.3. Colorectal Cancer
    • 4.4.4. Prostate Cancer
    • 4.4.5. Melanoma
    • 4.4.6. Ovarian Cancer
    • 4.4.7. Pancreatic Cancer
    • 4.4.8. Kidney Cancer
    • 4.4.9. Liver Cancer
    • 4.4.10. Others
  • 4.5. North America Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospitals
    • 4.5.2. Cancer Treatment Centers
    • 4.5.3. Specialty Clinics
    • 4.5.4. Research Institutes
    • 4.5.5. Others
  • 4.6. North America Metastatic Cancer Drug Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 4.6.2. U.S. Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.3. U.S. Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 4.6.4. U.S. Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 4.6.5. U.S. Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 4.6.6. Canada Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 4.6.7. Canada Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.8. Canada Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 4.6.9. Canada Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 4.6.10. Canada Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 5.1. Europe Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 5.1.1. Oral
    • 5.1.2. Injectable
    • 5.1.3. Others
  • 5.2. Europe Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Retail Pharmacies
    • 5.2.3. Online Pharmacies
    • 5.2.4. Specialty Pharmacies
  • 5.3. Europe Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 5.3.1. Chemotherapy
    • 5.3.2. Targeted Therapy
    • 5.3.3. Immunotherapy
    • 5.3.4. Hormonal Therapy
    • 5.3.5. Monoclonal Antibodies
    • 5.3.6. Angiogenesis Inhibitors
    • 5.3.7. Cancer Vaccines
    • 5.3.8. Others
  • 5.4. Europe Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 5.4.1. Breast Cancer
    • 5.4.2. Lung Cancer
    • 5.4.3. Colorectal Cancer
    • 5.4.4. Prostate Cancer
    • 5.4.5. Melanoma
    • 5.4.6. Ovarian Cancer
    • 5.4.7. Pancreatic Cancer
    • 5.4.8. Kidney Cancer
    • 5.4.9. Liver Cancer
    • 5.4.10. Others
  • 5.5. Europe Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospitals
    • 5.5.2. Cancer Treatment Centers
    • 5.5.3. Specialty Clinics
    • 5.5.4. Research Institutes
    • 5.5.5. Others
  • 5.6. Europe Metastatic Cancer Drug Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.2. Germany Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.3. Germany Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.4. Germany Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.5. Germany Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.6. Italy Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.7. Italy Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.8. Italy Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.9. Italy Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.10. Italy Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.11. France Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.12. France Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.13. France Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.14. France Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.15. France Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.16. U.K. Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.17. U.K. Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.18. U.K. Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.19. U.K. Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.20. U.K. Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.21. Spain Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.22. Spain Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.23. Spain Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.24. Spain Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.25. Spain Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.26. Russia Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.27. Russia Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.28. Russia Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.29. Russia Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.30. Russia Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 5.6.31. Rest of Europe Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 5.6.32. Rest of Europe Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.33. Rest of Europe Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 5.6.34. Rest of Europe Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 5.6.35. Rest of Europe Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 6.1.1. Oral
    • 6.1.2. Injectable
    • 6.1.3. Others
  • 6.2. Asia Pacific Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Retail Pharmacies
    • 6.2.3. Online Pharmacies
    • 6.2.4. Specialty Pharmacies
  • 6.3. Asia Pacific Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 6.3.1. Chemotherapy
    • 6.3.2. Targeted Therapy
    • 6.3.3. Immunotherapy
    • 6.3.4. Hormonal Therapy
    • 6.3.5. Monoclonal Antibodies
    • 6.3.6. Angiogenesis Inhibitors
    • 6.3.7. Cancer Vaccines
    • 6.3.8. Others
  • 6.4. Asia Pacific Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 6.4.1. Breast Cancer
    • 6.4.2. Lung Cancer
    • 6.4.3. Colorectal Cancer
    • 6.4.4. Prostate Cancer
    • 6.4.5. Melanoma
    • 6.4.6. Ovarian Cancer
    • 6.4.7. Pancreatic Cancer
    • 6.4.8. Kidney Cancer
    • 6.4.9. Liver Cancer
    • 6.4.10. Others
  • 6.5. Asia Pacific Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospitals
    • 6.5.2. Cancer Treatment Centers
    • 6.5.3. Specialty Clinics
    • 6.5.4. Research Institutes
    • 6.5.5. Others
  • 6.6. Asia Pacific Metastatic Cancer Drug Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.2. China Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.3. China Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.4. China Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.5. China Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 6.6.6. Japan Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.7. Japan Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.8. Japan Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.9. Japan Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.10. Japan Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 6.6.11. South Korea Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.12. South Korea Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.13. South Korea Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.14. South Korea Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.15. South Korea Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 6.6.16. India Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.17. India Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.18. India Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.19. India Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.20. India Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 6.6.21. Southeast Asia Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.22. Southeast Asia Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.23. Southeast Asia Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.24. Southeast Asia Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.25. Southeast Asia Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 6.6.26. Rest of SAO Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 6.6.27. Rest of SAO Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.28. Rest of SAO Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 6.6.29. Rest of SAO Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 6.6.30. Rest of SAO Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 7.1. Latin America Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 7.1.1. Oral
    • 7.1.2. Injectable
    • 7.1.3. Others
  • 7.2. Latin America Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Retail Pharmacies
    • 7.2.3. Online Pharmacies
    • 7.2.4. Specialty Pharmacies
  • 7.3. Latin America Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 7.3.1. Chemotherapy
    • 7.3.2. Targeted Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Hormonal Therapy
    • 7.3.5. Monoclonal Antibodies
    • 7.3.6. Angiogenesis Inhibitors
    • 7.3.7. Cancer Vaccines
    • 7.3.8. Others
  • 7.4. Latin America Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 7.4.1. Breast Cancer
    • 7.4.2. Lung Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Prostate Cancer
    • 7.4.5. Melanoma
    • 7.4.6. Ovarian Cancer
    • 7.4.7. Pancreatic Cancer
    • 7.4.8. Kidney Cancer
    • 7.4.9. Liver Cancer
    • 7.4.10. Others
  • 7.5. Latin America Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospitals
    • 7.5.2. Cancer Treatment Centers
    • 7.5.3. Specialty Clinics
    • 7.5.4. Research Institutes
    • 7.5.5. Others
  • 7.6. Latin America Metastatic Cancer Drug Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 7.6.2. Brazil Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.3. Brazil Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 7.6.4. Brazil Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 7.6.5. Brazil Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 7.6.6. Mexico Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 7.6.7. Mexico Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.8. Mexico Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 7.6.9. Mexico Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 7.6.10. Mexico Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 7.6.11. Argentina Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 7.6.12. Argentina Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.13. Argentina Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 7.6.14. Argentina Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 7.6.15. Argentina Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 7.6.16. Rest of LATAM Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 7.6.17. Rest of LATAM Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.18. Rest of LATAM Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 7.6.19. Rest of LATAM Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 7.6.20. Rest of LATAM Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Metastatic Cancer Drug Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa Metastatic Cancer Drug Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033
    • 8.1.1. Oral
    • 8.1.2. Injectable
    • 8.1.3. Others
  • 8.2. Middle East & Africa Metastatic Cancer Drug Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Retail Pharmacies
    • 8.2.3. Online Pharmacies
    • 8.2.4. Specialty Pharmacies
  • 8.3. Middle East & Africa Metastatic Cancer Drug Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033
    • 8.3.1. Chemotherapy
    • 8.3.2. Targeted Therapy
    • 8.3.3. Immunotherapy
    • 8.3.4. Hormonal Therapy
    • 8.3.5. Monoclonal Antibodies
    • 8.3.6. Angiogenesis Inhibitors
    • 8.3.7. Cancer Vaccines
    • 8.3.8. Others
  • 8.4. Middle East & Africa Metastatic Cancer Drug Market Outlook, by Cancer Type, Value (US$ Bn), 2020-2033
    • 8.4.1. Breast Cancer
    • 8.4.2. Lung Cancer
    • 8.4.3. Colorectal Cancer
    • 8.4.4. Prostate Cancer
    • 8.4.5. Melanoma
    • 8.4.6. Ovarian Cancer
    • 8.4.7. Pancreatic Cancer
    • 8.4.8. Kidney Cancer
    • 8.4.9. Liver Cancer
    • 8.4.10. Others
  • 8.5. Middle East & Africa Metastatic Cancer Drug Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospitals
    • 8.5.2. Cancer Treatment Centers
    • 8.5.3. Specialty Clinics
    • 8.5.4. Research Institutes
    • 8.5.5. Others
  • 8.6. Middle East & Africa Metastatic Cancer Drug Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 8.6.2. GCC Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.3. GCC Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 8.6.4. GCC Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 8.6.5. GCC Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 8.6.6. South Africa Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 8.6.7. South Africa Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.8. South Africa Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 8.6.9. South Africa Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 8.6.10. South Africa Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 8.6.11. Egypt Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 8.6.12. Egypt Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.13. Egypt Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 8.6.14. Egypt Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 8.6.15. Egypt Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 8.6.16. Nigeria Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 8.6.17. Nigeria Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.18. Nigeria Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 8.6.19. Nigeria Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 8.6.20. Nigeria Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
    • 8.6.21. Rest of Middle East Metastatic Cancer Drug Market Outlook, by Route of Administration, 2020-2033
    • 8.6.22. Rest of Middle East Metastatic Cancer Drug Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.23. Rest of Middle East Metastatic Cancer Drug Market Outlook, by Drug Class, 2020-2033
    • 8.6.24. Rest of Middle East Metastatic Cancer Drug Market Outlook, by Cancer Type, 2020-2033
    • 8.6.25. Rest of Middle East Metastatic Cancer Drug Market Outlook, by End User, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. F. Hoffmann-La Roche AG
    • 9.4.3. Merck & Co., Inc.
    • 9.4.4. AbbVie Inc.
    • 9.4.5. Bayer AG
    • 9.4.6. AstraZeneca plc
    • 9.4.7. Novartis AG
    • 9.4.8. Bristol-Myers Squibb Company
    • 9.4.9. Takeda Pharmaceutical Company Limited
    • 9.4.10. Eli Lilly and Company
    • 9.4.11. Amgen Inc.
    • 9.4.12. Astellas Pharma Inc.
    • 9.4.13. Eisai Co., Ltd.
    • 9.4.14. Incyte Corporation
    • 9.4.15. Ipsen S.A.

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기